Evidence map›Paper›PMID 26858580›Full record

ArticleJournal of equine science2015

Quantification of horse plasma proteins altered by xylazine using the fluorogenic derivatization-liquid chromatography-tandem mass spectrometry.

Miwako Mori, Tomoko Ichibangase, Shozo Yamashita, Isao Kijima-Suda, Masahiro Kawahara, Kazuhiro Imai

Open access · diamondAbstract read
In one paragraph

Article in Journal of equine science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Miwako MoriLaboratory of Bio-analytical Chemistry, Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo 202-8585, Japan; Laboratory of Proteomics Analysis, Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo 202-8585, Japan; Laboratory of Racing Chemistry, Tochigi 320-0851, Japan.
Tomoko IchibangaseLaboratory of Proteomics Analysis, Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo 202-8585, Japan.
Shozo YamashitaLaboratory of Racing Chemistry, Tochigi 320-0851, Japan.
Isao Kijima-SudaLaboratory of Racing Chemistry, Tochigi 320-0851, Japan.
Masahiro KawaharaLaboratory of Bio-analytical Chemistry, Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo 202-8585, Japan.
Kazuhiro ImaiLaboratory of Proteomics Analysis, Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo 202-8585, Japan.
Laboratory of Racing Chemistry · JPMusashino University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the doping tests currently used in horse racing, prohibited substances or their metabolites are usually directly detected in urine or blood samples. However, despite their lasting pharmaceutical effects, some prohibited substances are rapidly eliminated from horse urine and blood, making them difficult to detect. Therefore, new indirect biomarkers for doping, such as plasma proteins that are increased by the prohibited substances, have recently attracted much attention. Here, a fluorogenic derivatization-liquid chromatography-tandem mass spectrometry (FD-LC-MS/MS) method was adopted for horse plasma proteomics analysis, in order to identify plasma proteins whose concentrations were altered in response to xylazine in Thoroughbred horses. Xylazine, which is rapidly absorbed and eliminated and has possibility of the change in the levels of plasma proteins, was selected as a model drug. Of the ten plasma proteins identified, four proteins, including three acute phase proteins (haptoglobin, ceruloplasmin, and α-2-macroglobulin-like), were significantly increased after xylazine administration. Therefore, our present approach might be useful in identifying indirect biomarkers of drug administration.

Indexed as

dopingFD-LC-MS/MSplasma proteomicsxylazine

Identifiers

PMID26858580
PMCPMC4739145
OpenAlexW2343307213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.